present to please silence your cell phones, Blackberries and other devices if you have not
already done so. I would also like to identify the FDA press contact, Ms. Karen Reilly,
who is standing on my left. Thank you very much. I would like now to have
introductions by members and consultants around the table. Dr. Parks, would you mind
everyone again that even though this is a public meeting, for the public and everyone in
the audience, please do not cross over the rope to approach the panel members at any
time during the meeting today including the breaks. Thank you.
DR. BURMAN: Good morning. I would like first to remind everyone
DR. KONSTAM: Mark Konstam, Tufts Medical Center, Cardiology.
DR. HENDERSON: Jessica Henderson, Consumer Representative.
MR PROSCHAN: Michael Proschan, Statistician at the National Institute
CALL TO ORDER AND INTRODUCTIONS
KENNETH BURMAN, M.D.
DR. TRAN: Good morning. Before we start, I just want to remind
DR. PARKS: Mary Parks, Director of Division of Metabolism and
DR. JOFFE: Hylton Joffe, Lead Medical Officer for the diabetes drug
group in FDA.
DR. LOWY: Naomi Lowy, Medical Officer, Division of Metabolism and
of Allergy and Infectious Diseases.
DR. FLEGAL: Kathrine Flegal, Epidemiologist at the Centers for Disease
Control and Prevention.
Scribes, LLC Toll Free 1-800-675-8846 www.scribesllc.com